|
||||
![]() Bavituximab is also undergoing clinical trials for the treatment of breast cancer. Additionally, researchers reported additional evidence that Peregrine’s PS-targeting antibodies exert strong anti-tumor potential. The already encouraging data released in February indicated that in the Phase 2 study, there were seven objective tumor responses among 17 evaluable patients. That number has now risen to 11 responses among 17 after additional treatment cycles. The trial is now enrolling additional NSCLC patients as part of an expanded second study. NEXT PAGE >> Related headlines Komen O.C. receives 10K donation, announces board ‘OC METRO Minute,’ April 21: Rapid breast cancer therapy device growth expected in Asian Women’s Day of Self-Esteem Orange County United Way gears up for annual breakfast Newport Beach’s Oral Cancer Foundation wages war against cigarettes |
||||